AVEO Oncology Company Profile
AVEO Oncology (NASDAQ:AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsâ lives. AVEOâs proprietary Human Response Platform⢠provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the companyâs website at www.aveooncology.com.
News Articles
AVEO Oncology to Present at the Barclays Global Healthcare Conference
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March...
AVEO Oncology to Present at the UBS Annual Global Life Sciences Conference
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the UBS Annual Global Life Sciences Conference on Thursday, S...
AVEO Oncology to Present at the Morgan Stanley Global Healthcare Conference
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, Se...
AVEO Oncology to Present at the 2013 RBC Capital Markets’ Healthcare Conference
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wedn...
AVEO Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference
AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference...
AVEO Oncology to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference o...
AVEO Oncology to Present at the Jefferies 2012 Global Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, J...
AVEO Oncology to Present at the Canaccord Genuity 32nd Annual Growth Conference
AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 32nd Annual Growth Conference on Thursd...
Drugs and Medications
Neutrexin (trimetrexate glucuronate for injection) [MedImmune Oncology, Inc.]
NEUTREXIN (trimetrexate glucuronate for injection)
Carboplatin [Bedford Laboratories]
CARBOplatin Injection
Carboplatin injection [Sun Pharma Global Inc.]
Carboplatin Injection
Carboplatin [Bedford Laboratories]
CARBOplatin for Injection USP
Carboplatin [APP Pharmaceuticals, LLC]
CARBOPLATININJECTIONRx only
PubMed Articles
Deal watch: Aveo and Astellas to develop VEGF inhibitor for renal cell carcinoma.
Trastuzumab beyond progression: a challenge to translational oncology?
The history of oncology by theo wagener.
Adjuvant Chemotherapy for Stage II Colon Cancer: Less Complicated Than We Thought.
Prognosis of colorectal cancer with peritoneal carcinomatosis: is a new staging necessary?
Clinical Trials
Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.
The purpose of this study is to demonstrate the safety and benefit of auto-transfusion filtered blood in patients undergoing major surgical oncology procedures.
Cephalic Phase of Oncology Patients Before and After Chemotherapy as Compared to Healthy Controls
The objective of this trial is to examine the cephalic phase insulin response (CPIR) and pancreatic polypeptide (PP) release as indicators of the cephalic phase occurrence and magnitude to...
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
RATIONALE: Developing a way to track patients enrolled in Children's Oncology Group studies will help doctors gather long-term follow-up information and may help the study of cancer in the...
Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations
The purpose of this study is to evaluate the effectiveness of a two-dose regimen of Procrit prior to a major surgical oncology operation.
This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.
Companies
AVEO Oncology (NASDAQ:AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsâ lives. AVEOâ...
AVEO Oncology & Astellas Pharma Inc.
In February 2011, AVEO and Astellas entered into a worldwide agreement to develop and commercialize tivozanib outside of Asia for the treatment of a broad range of cancers. Tivoza...
AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc.
OncLive is the official website for Intellisphereâs Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary O...
More Information about "AVEO Oncology" on BioPortfolio
We have published hundreds of AVEO Oncology news stories on BioPortfolio along with dozens of AVEO Oncology Clinical Trials and PubMed Articles about AVEO Oncology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AVEO Oncology Companies in our database. You can also find out about relevant AVEO Oncology Drugs and Medications on this site too.
